Cannabis 2.0: Minor Cannabinoids and the Next Regulatory Frontier

Do you have clients in the marijuana or hemp industry? You may be familiar with federal and even state regulations regarding THC and CBD, but what about all those other cannabinoids? The newest frontier in cannabis is the so-called minor cannabinoids, from CBN to Delta-8. While minor cannabinoids naturally occur in the cannabis plant, they do so in trace quantities. Recently, cannabis companies have begun synthesizing these minor cannabinoids using more readily available cannabinoids such as CBD.

As products containing synthesized minor cannabinoids have begun to flood the market, regulators have taken notice. What are minor cannabinoids, and how are they produced, utilized, marketed, and sold? How are states responding to the proliferation of products containing lab-synthesized cannabinoids? What is the federal government’s position on synthetic cannabinoids? What do companies that sell products containing synthesized minor cannabinoids need to know?

Attend this program and learn which states prohibit or regulate minor cannabinoids, what the federal government has to say, and how attorneys can help their clients navigate this developing regulatory landscape. Attorneys with an intermediate background who represent clients in the cannabis or hemp industry, or those representing clients who want to add synthesized minor cannabinoids to a non-cannabis product, are encouraged to attend this cutting-edge program.

Learning Objectives:

• Review the latest on synthesized minor cannabinoids
• Examine the federal government’s role and synthesize minor cannabinoids
• Discover state-by-state regulation of synthesized minor cannabinoids